FMT hints at a peanut-allergy pathway
A 15-adult phase 1 study found higher peanut challenge thresholds in six participants after encapsulated FMT, while mouse experiments implicated bacterial bile-acid metabolism; efficacy remains unproven.
The 60-second version
A 15-adult phase 1 study found higher peanut challenge thresholds in six participants after encapsulated FMT, while mouse experiments implicated bacterial bile-acid metabolism in oral tolerance.
Key points
- The trial was open-label, nonrandomized and had no placebo group; its registered primary focus was safety and tolerability.
- Three of ten participants without antibiotics and three of five with antibiotics showed a higher reaction threshold.
- Responder microbiomes protected mice, and deleting a bacterial bile salt hydrolase gene removed that protection in the animal model.
- The study cannot establish human efficacy, uncommon harms or durability, and FMT should not be attempted outside regulated care.
Verdict. This is a credible translational lead from a small human safety study plus stronger animal mechanism work, not a peanut-allergy treatment ready for practice.
A phase 1 study in 15 adults with peanut allergy found higher food-challenge thresholds in six participants after screened, encapsulated fecal microbiota transplantation. The same paper used mouse experiments to identify bacterial bile-acid metabolism as a possible tolerance pathway. It is a useful safety and mechanism signal, not proof that FMT treats peanut allergy.
Human trialWhat was tested in people
ClinicalTrials.gov identifies NCT02960074 as a completed phase 1 trial in adults aged 18 to 40. Ten participants received frozen oral FMT capsules without antibiotic pretreatment; five received antibiotics first. Treatment took one or two days, with follow-up and repeat double-blind, placebo-controlled food challenges.
| No antibiotic pretreatment | 3 of 10 participants had an increased peanut-reactivity threshold. |
|---|---|
| Antibiotic pretreatment | 3 of 5 participants had an increased threshold. |
| Registered primary outcome | FMT-related adverse events of grade 2 or above over 12 months. |
| Design | Open-label, nonrandomized, single-group study with no placebo comparator. |
The paper reported no safety issues in this sample. That statement is bounded by the sample size and eligibility rules: the trial excluded people with a history of the most severe peanut anaphylaxis and several chronic or immune conditions. It cannot establish uncommon harms or broad safety.
SignalsWhat changed in responders
Participants classified as responders had more tolerance-associated RORγt-positive regulatory T cells and fewer type 2 helper T cells. They also showed microbiome and bile-acid-metabolite patterns that gave the researchers a candidate mechanism to test. In 15 people, these remain exploratory associations rather than validated predictors of response.
Animal mechanismWhat the mouse experiments added
Mice given post-FMT microbiomes from human responders were protected in a food-allergy model. Protection tracked with regulatory T cells, Bacteroides colonization and increased bile-acid metabolites. When researchers deleted a bile salt hydrolase gene in a candidate protective Bacteroides strain, allergy suppression disappeared in mice.
The gene-deletion result strengthens causality in the mouse model; it does not turn a 15-person phase 1 trial into proof of human efficacy.
Evidence boundaryWhat remains unknown
- There was no randomized placebo group, so the size of any human treatment effect is unknown.
- The groups contained only ten and five people; percentages are unstable and not suitable for clinical decisions.
- The durability of increased challenge thresholds and their effect on real-world accidental exposures need confirmation.
- The registered record lists no posted results, so the peer-reviewed paper is the result source and full adverse-event detail should be reviewed in context.
- Causal evidence for bile salt hydrolase comes from mice; human metabolism and immune responses may differ.
TakeawayWhat patients should do now
People with peanut allergy should continue their established avoidance plan, carry prescribed rescue medication and follow an allergy specialist's advice. The study points toward larger controlled trials and perhaps safer, defined bacterial or metabolite therapies. It does not support self-treatment with donor stool, commercial microbiome products or antibiotics.